

# Blaise A Clarke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3633885/publications.pdf>

Version: 2024-02-01

147  
papers

9,709  
citations

41258

49  
h-index

38300

95  
g-index

148  
all docs

148  
docs citations

148  
times ranked

13832  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. <i>New England Journal of Medicine</i> , 2009, 360, 2719-2729.	13.9	706
2	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	1.8	676
3	Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. <i>Cancer Research</i> , 2011, 71, 3364-3376.	0.4	662
4	Recurrent Somatic <i>DICER1</i> Mutations in Nonepithelial Ovarian Cancers. <i>New England Journal of Medicine</i> , 2012, 366, 234-242.	13.9	401
5	Germline and somatic <i>SMARCA4</i> mutations characterize small cell carcinoma of the ovary, hypercalcemic type. <i>Nature Genetics</i> , 2014, 46, 438-443.	9.4	383
6	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	5.1	335
7	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in <i>SMARCA4</i> . <i>Nature Genetics</i> , 2014, 46, 427-429.	9.4	298
8	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and <i>BRCA1</i> loss. <i>Modern Pathology</i> , 2009, 22, 393-402.	2.9	241
9	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , 2008, 39, 1239-1251.	1.1	231
10	Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1503-1513.	3.0	231
11	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	3.6	211
12	Hotspot activating <i>PRKD1</i> somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014, 46, 1166-1169.	9.4	188
13	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <i>HER2</i> targeting in 19% of carcinomas. <i>Journal of Pathology</i> , 2013, 229, 111-120.	2.1	169
14	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015, 28, 1101-1122.	2.9	164
15	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. <i>Human Pathology</i> , 2009, 40, 1070-1081.	1.1	147
16	A distinct innate lymphoid cell population regulates tumor-associated T cells. <i>Nature Medicine</i> , 2017, 23, 368-375.	15.2	131
17	Novel <i>PRKD</i> gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 845-856.	1.5	128
18	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 925-934.	3.2	125

#	ARTICLE	IF	CITATIONS
19	Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. <i>JAMA Surgery</i> , 2021, 156, 157.	2.2	118
20	No small surprise—small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. <i>Journal of Pathology</i> , 2014, 233, 209-214.	2.1	117
21	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173776.	3.4	116
22	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. <i>Cancer</i> , 2014, 120, 3932-3939.	2.0	114
23	DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1178-1187.	2.1	114
24	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , 2014, 27, 255-261.	2.9	110
25	The Histomorphology of Lynch Syndrome-associated Ovarian Carcinomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1173-1181.	2.1	108
26	Hypoxic Activation of the PERK/eIF2 $\gamma$ Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3. <i>Clinical Cancer Research</i> , 2013, 19, 6126-6137.	3.2	105
27	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011, 24, 512-521.	2.9	95
28	Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. <i>Journal of Clinical Pathology</i> , 2010, 63, 410-415.	1.0	93
29	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2012, 10, 33.	1.8	93
30	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. <i>Journal of Pathology</i> , 2014, 232, 473-481.	2.1	81
31	Somatic <i>BRCA1/2</i> Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. <i>Journal of Clinical Oncology</i> , 2017, 35, 1240-1249.	0.8	79
32	Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5685-5696.	3.2	76
33	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. <i>Nature Communications</i> , 2019, 10, 558.	5.8	76
34	Histologic Artifacts in Abdominal, Vaginal, Laparoscopic, and Robotic Hysterectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2011, 35, 115-126.	2.1	74
35	Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. <i>Gynecologic Oncology</i> , 2014, 133, 229-233.	0.6	73
36	In-Depth Proteomics of Ovarian Cancer Ascites: Combining Shotgun Proteomics and Selected Reaction Monitoring Mass Spectrometry. <i>Journal of Proteome Research</i> , 2011, 10, 2286-2299.	1.8	72

#	ARTICLE	IF	CITATIONS
37	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. <i>Genome Medicine</i> , 2018, 10, 81.	3.6	72
38	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012, 118, 681-688.	2.0	71
39	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014, 32, 243-249.	1.2	70
40	In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 173-185.	1.3	70
41	Prevalence of Loss of Expression of DNA Mismatch Repair Proteins in Primary Epithelial Ovarian Tumors. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 524-531.	0.9	66
42	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. <i>Gynecologic Oncology</i> , 2015, 137, 216-222.	0.6	65
43	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. <i>Cancer</i> , 2014, 120, 603-610.	2.0	64
44	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	2.0	62
45	Neuroendocrine tumors of the gynecologic tract: Select topics. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 224-233.	1.0	61
46	MicroRNA-196b Regulates the Homeobox B7-Vascular Endothelial Growth Factor Axis in Cervical Cancer. <i>PLoS ONE</i> , 2013, 8, e67846.	1.1	60
47	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. <i>Modern Pathology</i> , 2007, 20, 1156-1165.	2.9	58
48	Identifying Lynch Syndrome in Patients With Ovarian Carcinoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 378-386.	2.4	52
49	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. <i>Histopathology</i> , 2016, 69, 727-738.	1.6	52
50	Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 1823-1833.	2.9	52
51	High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. , 2019, 7, 357.		52
52	International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S114-S122.	0.9	52
53	Identifying Lynch Syndrome in Patients With Endometrial Carcinoma. <i>Advances in Anatomic Pathology</i> , 2012, 19, 231-238.	2.4	51
54	Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	51

#	ARTICLE	IF	CITATIONS
55	Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. <i>Cancer</i> , 2012, 118, 3105-3115.	2.0	50
56	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	1.2	50
57	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015, 139, 268-274.	0.6	50
58	Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors. <i>Modern Pathology</i> , 2013, 26, 95-105.	2.9	49
59	Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 767-775.	3.4	46
60	Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). <i>Cancers</i> , 2012, 4, 821-845.	1.7	44
61	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. <i>Clinical Cancer Research</i> , 2018, 24, 6168-6174.	3.2	44
62	Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma. <i>Modern Pathology</i> , 2020, 33, 1207-1219.	2.9	43
63	Developing a Prognostic Micro-RNA Signature for Human Cervical Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0123946.	1.1	42
64	Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. <i>American Journal of Surgical Pathology</i> , 2018, 42, 137-139.	2.1	41
65	Uterine adenosarcomas: A dual-institution update on staging, prognosis and survival. <i>Gynecologic Oncology</i> , 2013, 131, 634-639.	0.6	36
66	Clinical, morphological and immunohistochemical evidence that smallâ€cell carcinoma of the ovary of hypercalcaemic type (<scp>SCCOHT</scp>) may be a primitive germâ€cell neoplasm. <i>Histopathology</i> , 2017, 70, 1147-1154.	1.6	36
67	Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 116-123.	0.9	36
68	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. <i>Human Pathology</i> , 2014, 45, 1258-1268.	1.1	34
69	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	0.6	34
70	Ovarian immature teratoma: Treatment and outcome in a single institutional cohort. <i>Gynecologic Oncology</i> , 2011, 123, 50-53.	0.6	33
71	Systemic Anaplastic Large Cell Lymphoma Presenting With Conjunctival Involvement. <i>JAMA Ophthalmology</i> , 2003, 121, 568.	2.6	32
72	N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer. <i>Cell Systems</i> , 2019, 8, 345-351.e4.	2.9	31

#	ARTICLE	IF	CITATIONS
73	Clear cell (glycogen-rich) gastric adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2004, 8, 69-73.	0.6	29
74	Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing. <i>Histopathology</i> , 2014, 65, 228-239.	1.6	29
75	TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 346-352.	1.2	29
76	Microscopic extraovarian sex cord proliferations: an undescribed phenomenon. <i>Histopathology</i> , 2015, 66, 555-564.	1.6	28
77	Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low-versus High-Volume Ascites. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	27
78	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. <i>BMC Cancer</i> , 2014, 14, 982.	1.1	27
79	Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. <i>Oncolmmunology</i> , 2019, 8, e1665460.	2.1	27
80	VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. <i>British Journal of Cancer</i> , 2017, 116, 1065-1076.	2.9	26
81	IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function. <i>Cancer Immunology Research</i> , 2020, 8, 321-333.	1.6	26
82	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. <i>Seminars in Diagnostic Pathology</i> , 2009, 26, 165-176.	1.0	25
83	Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 560-567.	0.9	25
84	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016, 141, 559-563.	0.6	25
85	Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 111-117.	0.4	25
86	Biologically-Targeted Detection of Primary and Micro-Metastatic Ovarian Cancer. <i>Theranostics</i> , 2013, 3, 420-427.	4.6	24
87	Expanding the morphological spectrum of ovarian microcystic stromal tumour. <i>Histopathology</i> , 2019, 74, 443-451.	1.6	24
88	A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. <i>American Journal of Pathology</i> , 2018, 188, 1120-1131.	1.9	23
89	Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). <i>Pathology</i> , 2018, 50, 222-237.	0.3	23
90	Endometrial Giant Cell Carcinoma: A Case Series and Review of the Spectrum of Endometrial Neoplasms Containing Giant Cells. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1132-1138.	2.1	20

#	ARTICLE	IF	CITATIONS
91	Chromosomal instability as a prognostic marker in cervical cancer. <i>BMC Cancer</i> , 2015, 15, 361.	1.1	18
92	The predictive value of nadir neutrophil count during treatment of cervical cancer: Interactions with tumor hypoxia and interstitial fluid pressure (IFP). <i>Clinical and Translational Radiation Oncology</i> , 2017, 6, 15-20.	0.9	16
93	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11002-11002.	0.8	16
94	A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3061-3061.	0.8	16
95	The Significance of Tumoral ERCC1 Status in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiation Therapy: A Multicenter Clinicopathologic Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 721-727.	0.4	15
96	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. <i>Cancer</i> , 2020, 126, 4886-4894.	2.0	15
97	Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program. <i>Molecular Oncology</i> , 2021, 15, 80-90.	2.1	14
98	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017, 8, 84659-84670.	0.8	13
99	Tubulo-squamous Polyp With Mucinous and Goblet Cell Differentiation. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 518-519.	0.9	12
100	Canadian Association of Pathologists's Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2014, 142, 629-633.	0.4	12
101	An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 242-252.	1.2	12
102	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 71-83.	0.5	11
103	Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 659-667.	0.3	10
104	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 136, 311-316.	0.6	9
105	Genomic profiling identifies GPC5 amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 69-78.	1.3	9
106	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. <i>Gynecologic Oncology</i> , 2021, 161, 221-227.	0.6	9
107	Leiomyosarcoma of the Broad Ligament With Osteoclast-like Giant Cells and Rhabdoid Cells. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 432-437.	0.9	7
108	Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review. <i>Diagnostic Pathology</i> , 2019, 14, 30.	0.9	7

#	ARTICLE	IF	CITATIONS
109	Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC).. Journal of Clinical Oncology, 2012, 30, 5010-5010.	0.8	7
110	Letter to the editor regarding "Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression". Modern Pathology, 2011, 24, 1281-1282.	2.9	6
111	Ovarian hilar proliferations resembling Sertoli cell tumours: microscopic neoplasms or non-neoplastic remnants?. Histopathology, 2016, 68, 596-602.	1.6	6
112	Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. Mod Pathol 2020; 33:871-879. Modern Pathology, 2021, 34, 1031-1032.	2.9	6
113	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. Cancer, 2021, 127, 3082-3091.	2.0	6
114	Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. Journal of Clinical Oncology, 2017, 35, 5522-5522.	0.8	6
115	Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers. International Journal of Gynecological Cancer, 2020, 30, 1951-1958.	1.2	5
116	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. Gynecologic Oncology, 2020, 159, 539-545.	0.6	4
117	Cryptococemia Resulting in an Incomplete Abortion in an HIV-Positive Patient. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e97-e99.	0.7	3
118	Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers. Surgical Pathology Clinics, 2016, 9, 307-328.	0.7	3
119	Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. Journal of Ovarian Research, 2022, 15, 50.	1.3	3
120	Displaced Granulosa Cells Within the Ovarian Stroma in a BRCA1 Mutation Carrier. International Journal of Gynecological Pathology, 2014, 33, 423-424.	0.9	2
121	Neoadjuvant therapy in gynaecological malignancies: What pathologists need to know. Journal of Clinical Pathology, 2019, 72, 102-111.	1.0	2
122	Validation of BRCA testing on cytologic samples of high-grade serous carcinoma. Cancer Cytopathology, 2021, 129, 907-913.	1.4	2
123	Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).. Journal of Clinical Oncology, 2014, 32, 5506-5506.	0.8	2
124	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, 1532-1532.	0.8	2
125	Comprehensive molecular assessment of mismatch repair deficiency in Lynch-associated ovarian cancers using next-generation sequencing (NGS) panel.. Journal of Clinical Oncology, 2020, 38, 1523-1523.	0.8	2
126	Ovarian carcinoma histotype in Lynch syndrome. Gynecologic Oncology Reports, 2017, 20, 140-141.	0.3	1



#	ARTICLE	IF	CITATIONS
127	Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100363.	0.7	1
128	Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100729.	0.3	1
129	Placenta increta mimicking placental site trophoblastic tumor. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1481-1485.	1.2	1
130	A Triage Assessment Strategy for the Management of Women With Endometrial Cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 348-354.	0.3	0
131	Mutations in <i>IDH1</i> and <i>IDH2</i> are not present in sporadic ovarian sex cord stromal tumours. <i>Histopathology</i> , 2015, 66, 897-898.	1.6	0
132	Gynecologic Pathology. <i>Surgical Pathology Clinics</i> , 2016, 9, ix-x.	0.7	0
133	Precursors of High-Grade Serous Carcinoma. , 2016, , 3-22.		0
134	Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, e22525-e22525.	0.8	0
135	Prognostic significance of high-risk human papilloma virus (HPV), p16, and p53 status in women with vulvar squamous cell carcinoma (VSCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5105-5105.	0.8	0
136	Brief family history questionnaire for identification of Lynch syndrome in women with newly diagnosed endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5026-5026.	0.8	0
137	Screening for Lynch syndrome in unselected women with endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5508-5508.	0.8	0
138	Adjuvant radiation for patients (pts) with high-grade serous ovarian cancer (HGSC) and T-cell infiltration.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5543-5543.	0.8	0
139	The CXCL12/CXCR4 pathway, bone marrow-derived myeloid cells, and survival in locally advanced cervical cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11122-11122.	0.8	0
140	Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1532-1532.	0.8	0
141	Molecular profiling and targeted therapy in advanced endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5589-5589.	0.8	0
142	Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5509-5509.	0.8	0
143	Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5579-5579.	0.8	0
144	Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5564-5564.	0.8	0

#	ARTICLE	IF	CITATIONS
145	P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.. Journal of Clinical Oncology, 2016, 34, 5550-5550.	0.8	0
146	Uterine Clear Cell Carcinoma. Molecular Pathology Library, 2017, , 123-142.	0.1	0
147	Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003082.	1.2	0